Gan & Lee Pharmaceuticals (SHA:603087) dosed the first subject for the phase I clinical trial of its GLR1023 injection, according to a Shanghai Stock Exchange filing on Thursday.
The drug, marketed as Cosentyx, is used to treat moderate to severe plaque psoriasis in adults. The trial aims to compare the similarity of the main pharmacokinetic parameters, immunogenicity and safety between a single subcutaneous injection of GLR1023 injection and secukinumab injection in healthy adult male subjects in China.
The Chinese pharmaceutical company invested 64.4 million yuan into the research and development of the drug, the filing said.
Shares of the company rose more than 2% in recent trade.
Price (RMB): ¥52.15, Change: ¥+1.3, Percent Change: +2.48%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。